UK markets closed
NIKKEI 225
39,341.54 -325.53 (-0.82%) HANG SENG
17,716.47 -373.46 (-2.06%) CRUDE OIL
81.51 +0.61 (+0.75%) GOLD FUTURES
2,337.10 +23.90 (+1.03%) DOW
39,205.87 +78.07 (+0.20%) Bitcoin GBP
48,889.70 +620.77 (+1.29%)
ABBV Jun 2025 240.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 10:21AM EDT. Market open.
Loading interactive chart…
- Zacks
FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma
Following the label expansion, AbbVie's (ABBV) Epkinly is the first bispecific antibody approved to treat relapsed/refractory (R/R) follicular lymphoma and R/R diffuse large B-cell lymphoma.
- Zacks
Merck's (MRK) Lung Cancer Candidate Faces FDA Rejection
The FDA's CRL to Merck (MRK) and its partner Daiichi Sankyo for the patritumab deruxtecan BLA is based on observations made on inspection of a third-party manufacturing facility.
- PR Newswire
AbbVie Acquires Celsius Therapeutics
AbbVie (NYSE: ABBV) announced today the acquisition of Celsius Therapeutics, Inc. ("Celsius"), a privately held biotechnology company pioneering new therapies for patients with inflammatory disease. Celsius' lead investigational asset is CEL383, a potential first-in-class anti-TREM1 antibody that has completed a Phase 1 clinical study for the treatment of IBD.
© 2024 Yahoo. All rights reserved.